Semaglutide and the Eye: Indian Expert Commentary.

Authors

  • Banshi Saboo Author
  • Rohit Saxena Author
  • Manoj Chawla Author
  • L Sreenivasamurthy Author
  • Jyoti Matalia Author

Keywords:

GLP-1, semaglutide, Ozempic, diabetic retinopathy, NAION

Abstract

There has been a significant change in the management algorithms and clinical use of semaglutide due to its multiple benefits includingglycemic reduction, weight loss, cardiovascular effects, renal protection, hepatic benefits amongst others. The role of semaglutide in popularising the class of GLP-1 receptor agonists cannot be denied. Despite the clear proven benefits, there has been some concernregarding potential eye-related adverse effects – particularly diabetic retinopathy and non-arteritic anterior ischemic optic neuropathy (NAION) with GLP-1 based therapies including semaglutide. This comprehensive review by a panel of expert diabetologists and ophthalmologists is an attempt to evaluate the available clinical data and arrive at a conclusion regarding the causal association of these adverse effects with the use of semaglutide (limited to the innovator brand of semaglutide in the doses of 0.25 mg, 0.5 mg and 1.0 mg for the use in people with type 2 diabetes mellitus) and provide guidance to every physician regarding its use.

References

1. Salvador R, Moutinho CG, Sousa C, Vinha AF, Carvalho M, Matos C. Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment. Pharmaceuticals. 2025 Mar 12;18(3):399.

2. World Health Organization. The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION). 2025 Jun.

3. Early Treatment Diabetic Retinopathy Study Design and Baseline Patient Characteristics. Ophthalmology. 1991 May;98(5):741–56.

4. Marathe PH, Gao HX, Close KL. American DiabetesAssociationStandards of MedicalC are in Diabetes 2017. J Diabetes. 2017 Apr 13;9(4):320–4.

5. Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global Prevalence and Major Risk Factors of Diabetic Retinopathy. Diabetes Care. 2012 Mar 1;35(3):556–64.

6. Sharma A, Parachuri N, Kumar N, Saboo B, Tripathi HN, Kuppermann BD, et al. Semaglutide and the risk of diabetic retinopathy—current perspective. Eye. 2022 Jan 9;36(1):10–1.

7. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine. 1993 Sep 30;329(14):977–86.

8. Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy. New England Journal of Medicine. 2000 Feb 10;342(6):381–9.

9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 Sep 12;352(9131):837–53.

10. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998 Sep 12;317(7160):703–13.

11. Makkar BM, Ch.Kumar V, Saboo B, Agarwal S. RSSDI clinical practice recommendations for management of type 2 diabetes mellitus 2022. International Journal of Diabetes in Developing Countries, . 2022;42(1):1–143.

12. ElSayed NA, McCoy RG, Aleppo G, Bajaj M, Balapattabi K, Beverly EA, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. Diabetes Care. 2025 Jan 1;48(Supplement_1):S181–206.

13. Sorli C, Harashima S ichi, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017 Apr;5(4):251–60.

14. Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017 May;5(5):341–54.

15. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021 Mar 18;384(11):989–1002.

16. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016 Nov 10;375(19):1834–44.

17. Kesavadev J, Unnikrishnan AG, Sanyal D, Aneja P, Saboo BD. Demystifying the Progression of Retinopathy with Glucagon-Like Peptide-1 Receptor Agonists. International Journal of Diabetes and Technology. 2022 Apr;1(2):53–5.

18. American Academy of Ophthalmology. Popular weight loss drug does not appear to worsen diabetic eye disease in most patients, new study suggests. 2023 Nov.

19. Silverii GA, Pala L, Cresci B, Mannucci E. Glucagon‐like peptide 1 ( GLP1 ) receptor agonists and risk for ischemic optic neuropathy: A meta‐analysis of randomised controlled trials. Diabetes Obes Metab. 2025 Feb 20;27(2):1005–9.

20. Saleem NUA, Khan M, Tague C, Akilimali A. The unseen risk of Ozempic: NAION and vision damage. Annals of Medicine & Surgery. 2025 Dec;87(12):7898–9.

21. Chen KY, Chan HC, Chan CM. Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence. Asia-Pacific Journal of Ophthalmology. 2025 Sep;100245.

22. Martin-Gutierrez MP, Petzold A, Saihan Z. NAION or not NAION? A literature review of pathogenesis and differential diagnosis of anterior ischaemic optic neuropathies. Eye. 2024 Feb 28;38(3):418–25.

23. Vilsbøll T, et al. Incidence of non-arteritic ischaemic optic neuropathy across completed phase 2, 3 and 4 trials evaluating the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide. 61st EASD Annual Meeting of the European Association for the Study of Diabetes. Diabetologia. 2025 Sep 26;68(S1):1–754.

24. Chou CC, Pan SY, Sheen YJ, Lin JF, Lin CH, Lin HJ, et al. Association between Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. Ophthalmology. 2025 Apr;132(4):381–8.

25. Abbass NJ, Nahlawi R, Shaia JK, Allan KC, Kaelber DC, Talcott KE, et al. The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy. Am J Ophthalmol. 2025 Jun;274:24–31.

26. Lieberman RA, Korona-Bailey J, Banaag A, Furhman B, Corrado R, Koehlmoos TP. Semaglutide Decreases Risk of Non-Arteritic Anterior Ischemic Optic Neuroapthy in Type 2 Diabetic Patients. Mil Med. 2025 Nov 11;

27. Cestari D, Dugan C, Pineles SL, Miller AM, Lee AG, Al-Zubidi N. Non-arteritic anterior ischemic optic neuropathy (NAION). EyeWiki, American Academy of Ophthalmology. 2025.

28. Centers for Disease Control and Prevention. ICD-10-CM: International Classification of Diseases, Tenth Revision, Clinical Modification. National Center for Health Statistics, Centers for Disease Control and Prevention. 2024.

29. American Academy of Ophthalmology. ‘Weight-loss drugs and eye health.’ AAO Newsroom. 2024;

30. North American Neuro-Ophthalmology Society. Semaglutide and NAION (patient brochure). NANOS. 2024 Aug;

31. World Health Organization. ‘Semaglutide medicines and non-arteritic anterior ischaemic optic neuropathy (NAION): statement following pharmacovigilance review.’ News release. 2025 Jun;

32. World Health Organization. WHO Model Lists of Essential Medicines. Geneva; 2025.

33. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023 Dec 14;389(24):2221–32.

Downloads

Published

2026-11-09

Similar Articles

11-20 of 21

You may also start an advanced similarity search for this article.